Dive into our repository of groundbreaking research papers, where we merge clinical expertise with data driven insights to revolutionize patient care and treatment strategies.
Explore the latest news about COTA, where our breakthroughs and collaborations lead the charge in transforming healthcare. Each mention underscores our role in pioneering data-driven solutions for real-world challenges.
COTA’s scientific contributions have once again been recognized by the American Society of Hematology (ASH) Annual Meeting and Exposition, one...
Medical oncologist and real-world data leader succeeds Miruna Sasu, whose leadership expanded COTA’s impact across life sciences. A Leader Rooted...
Cancer is a disease that respects no borders: it affects everyone around the world, no matter where they live. The...
COTA’s scientific contributions have once again been recognized by the American Society of Hematology (ASH) Annual Meeting and Exposition, one...
Medical oncologist and real-world data leader succeeds Miruna Sasu, whose leadership expanded COTA’s impact across life sciences. A Leader Rooted...
Real-world data (RWD) from electronic health records (EHRs) is increasingly recognized as a powerful asset for oncology research. It enables...
Summary During this episode of Real World Talk, host Kevin Keogh talks with Dr. Andrew Pecora of OMI (Outcomes Matter…
Summary During this episode of Real World Talk, host Zoe Li has a conversation with Michelle Hoiseth, the Chief Data…
Explore impactful case studies that highlight COTA’s innovative solutions in action. These stories illustrate the significant differences our data driven approach makes in patient care and healthcare improvement.
Much of today’s investigational cancer therapeutics originates in small biotechnology companies, most of which are innovative and agile by nature, but also lack the financial horsepower, resources, and infrastructure of…
Real-world data (RWD) in Oncology proves to be a vital source for clinical decisions and program decisions. COTA partnered with a Top 5 Pharma company to curate a custom multiple…
Despite advances in liquid biopsies, standard-of-care remains tissue-based genotyping, an approach that is relatively invasive, inconvenient, slow, and expensive
…
